Affimed Nv Stock Performance
| AFMD Stock | USD 0.88 0.01 1.12% |
The firm shows a Beta (market volatility) of 0.64, which signifies possible diversification benefits within a given portfolio. As returns on the market increase, Affimed NV's returns are expected to increase less than the market. However, during the bear market, the loss of holding Affimed NV is expected to be smaller as well. At this point, Affimed NV has a negative expected return of -0.79%. Please make sure to confirm Affimed NV's potential upside, day median price, and the relationship between the treynor ratio and accumulation distribution , to decide if Affimed NV performance from the past will be repeated at some point in the near future.
Risk-Adjusted Performance
Very Weak
Weak | Strong |
Over the last 90 days Affimed NV has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of weak performance in the last few months, the Stock's primary indicators remain rather sound which may send shares a bit higher in April 2025. The latest tumult may also be a sign of longer-term up-swing for the firm shareholders. ...more
| Begin Period Cash Flow | 190.3 M |
Affimed |
Affimed NV Relative Risk vs. Return Landscape
If you would invest 151.00 in Affimed NV on December 17, 2024 and sell it today you would lose (63.00) from holding Affimed NV or give up 41.72% of portfolio value over 90 days. Affimed NV is currently does not generate positive expected returns and assumes 4.1542% risk (volatility on return distribution) over the 90 days horizon. In different words, 37% of stocks are less volatile than Affimed, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Affimed NV Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Affimed NV's investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Affimed NV, and traders can use it to determine the average amount a Affimed NV's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = -0.1913
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns | AFMD |
Estimated Market Risk
| 4.15 actual daily | 37 63% of assets are more volatile |
Expected Return
| -0.79 actual daily | 0 Most of other assets have higher returns |
Risk-Adjusted Return
| -0.19 actual daily | 0 Most of other assets perform better |
Based on monthly moving average Affimed NV is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Affimed NV by adding Affimed NV to a well-diversified portfolio.
Affimed NV Fundamentals Growth
Affimed Stock prices reflect investors' perceptions of the future prospects and financial health of Affimed NV, and Affimed NV fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Affimed Stock performance.
| Return On Equity | -1.49 | ||||
| Return On Asset | -0.49 | ||||
| Operating Margin | (87.09) % | ||||
| Current Valuation | 1.34 M | ||||
| Shares Outstanding | 16.39 M | ||||
| Price To Earning | (2.04) X | ||||
| Price To Book | 0.77 X | ||||
| Price To Sales | 2.56 X | ||||
| Revenue | 8.28 M | ||||
| EBITDA | (102.38 M) | ||||
| Cash And Equivalents | 237.23 M | ||||
| Cash Per Share | 1.59 X | ||||
| Total Debt | 19.35 M | ||||
| Debt To Equity | 0.1 % | ||||
| Book Value Per Share | 1.05 X | ||||
| Cash Flow From Operations | (110.27 M) | ||||
| Earnings Per Share | (4.95) X | ||||
| Total Asset | 97.16 M | ||||
| Retained Earnings | (536.13 M) | ||||
| Current Asset | 78.33 M | ||||
| Current Liabilities | 8.94 M | ||||
About Affimed NV Performance
By analyzing Affimed NV's fundamental ratios, stakeholders can gain valuable insights into Affimed NV's financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if Affimed NV has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Affimed NV has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements.
Affimed N.V., a clinical-stage biopharmaceutical company, focuses on discovering and developing cancer immunotherapies in the United States, Germany, and rest of Europe. Affimed N.V. was founded in 2000 and is headquartered in Heidelberg, Germany. Affimed NV operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 197 people.Things to note about Affimed NV performance evaluation
Checking the ongoing alerts about Affimed NV for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Affimed NV help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Affimed NV generated a negative expected return over the last 90 days | |
| Affimed NV has some characteristics of a very speculative penny stock | |
| Affimed NV has high historical volatility and very poor performance | |
| Affimed NV has a very high chance of going through financial distress in the upcoming years | |
| The company reported the previous year's revenue of 8.28 M. Net Loss for the year was (105.94 M) with profit before overhead, payroll, taxes, and interest of 5.64 M. | |
| Affimed NV currently holds about 237.23 M in cash with (110.27 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 1.59, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Affimed NV has a frail financial position based on the latest SEC disclosures | |
| Latest headline from news.google.com: JPMorgan Chase Co. Lowers Day One Biopharmaceuticals Price Target to 34.00 - Defense World |
- Analyzing Affimed NV's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Affimed NV's stock is overvalued or undervalued compared to its peers.
- Examining Affimed NV's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Affimed NV's management team can have a significant impact on its success or failure. Reviewing the track record and experience of Affimed NV's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Affimed NV's stock. These opinions can provide insight into Affimed NV's potential for growth and whether the stock is currently undervalued or overvalued.
Complementary Tools for Affimed Stock analysis
When running Affimed NV's price analysis, check to measure Affimed NV's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Affimed NV is operating at the current time. Most of Affimed NV's value examination focuses on studying past and present price action to predict the probability of Affimed NV's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Affimed NV's price. Additionally, you may evaluate how the addition of Affimed NV to your portfolios can decrease your overall portfolio volatility.
| Commodity Directory Find actively traded commodities issued by global exchanges | |
| Global Correlations Find global opportunities by holding instruments from different markets | |
| Portfolio Rebalancing Analyze risk-adjusted returns against different time horizons to find asset-allocation targets | |
| Performance Analysis Check effects of mean-variance optimization against your current asset allocation | |
| Fundamental Analysis View fundamental data based on most recent published financial statements | |
| Portfolio Diagnostics Use generated alerts and portfolio events aggregator to diagnose current holdings | |
| Technical Analysis Check basic technical indicators and analysis based on most latest market data | |
| Portfolio File Import Quickly import all of your third-party portfolios from your local drive in csv format | |
| Portfolio Holdings Check your current holdings and cash postion to detemine if your portfolio needs rebalancing |